Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Phase II study of cisplatin/pemetrexed combined with bevacizumab followed by pemetrexed/bevacizumab maintenance therapy in patients with EGFR-wild advanced non-squamous non-small cell lung cancer

Phase II study of cisplatin/pemetrexed combined with bevacizumab followed by... Purpose This phase II study was performed to evaluate the efficacy and safety of cisplatin/pemetrexed combined with 15 mg/ kg of bevacizumab followed by pemetrexed/bevacizumab maintenance therapy as first-line chemotherapy in advanced non- squamous non-small cell lung cancer (NSCLC) limited to epidermal growth factor receptor (EGFR)-wild type. Patients and methods Fifty patients with advanced or metastatic EGFR-wild type NSCLC aged < 75 years old were enrolled 2 2 in the study. The patients were treated with four cycles of cisplatin (75 mg/m , day 1), pemetrexed (500 mg/m , days 1), and bevacizumab (15 mg/kg, day 1), every 3 weeks, followed by pemetrexed plus bevacizumab maintenance until progression for achieving a response over stable disease after induction chemotherapy. Results Partial response and stable disease were observed in 35 (objective response rate: 70, 95% CI: 55.4–82.1%) and 9 patients, respectively, and 39 (78%) patients received pemetrexed plus bevacizumab maintenance therapy. Median progres- sion-free survival and overall survival periods were 12.0 months (95% CI: 7.5–16.5 months) and 31.0 months (95% CI: 22.2–39.8 months), respectively. Grade 3 adverse events included neutropenia (14%), nausea (10%), anorexia (18%), and hypertension (8%). Coagulation disorder was observed in one patient, but all of these events were reversible and resulted in no http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cancer Chemotherapy and Pharmacology Springer Journals

Phase II study of cisplatin/pemetrexed combined with bevacizumab followed by pemetrexed/bevacizumab maintenance therapy in patients with EGFR-wild advanced non-squamous non-small cell lung cancer

Loading next page...
1
 
/lp/springer_journal/phase-ii-study-of-cisplatin-pemetrexed-combined-with-bevacizumab-Rhw6MHT1Kv

References (34)

Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer-Verlag GmbH Germany, part of Springer Nature
Subject
Medicine & Public Health; Oncology; Pharmacology/Toxicology; Cancer Research
ISSN
0344-5704
eISSN
1432-0843
DOI
10.1007/s00280-018-3573-0
Publisher site
See Article on Publisher Site

Abstract

Purpose This phase II study was performed to evaluate the efficacy and safety of cisplatin/pemetrexed combined with 15 mg/ kg of bevacizumab followed by pemetrexed/bevacizumab maintenance therapy as first-line chemotherapy in advanced non- squamous non-small cell lung cancer (NSCLC) limited to epidermal growth factor receptor (EGFR)-wild type. Patients and methods Fifty patients with advanced or metastatic EGFR-wild type NSCLC aged < 75 years old were enrolled 2 2 in the study. The patients were treated with four cycles of cisplatin (75 mg/m , day 1), pemetrexed (500 mg/m , days 1), and bevacizumab (15 mg/kg, day 1), every 3 weeks, followed by pemetrexed plus bevacizumab maintenance until progression for achieving a response over stable disease after induction chemotherapy. Results Partial response and stable disease were observed in 35 (objective response rate: 70, 95% CI: 55.4–82.1%) and 9 patients, respectively, and 39 (78%) patients received pemetrexed plus bevacizumab maintenance therapy. Median progres- sion-free survival and overall survival periods were 12.0 months (95% CI: 7.5–16.5 months) and 31.0 months (95% CI: 22.2–39.8 months), respectively. Grade 3 adverse events included neutropenia (14%), nausea (10%), anorexia (18%), and hypertension (8%). Coagulation disorder was observed in one patient, but all of these events were reversible and resulted in no

Journal

Cancer Chemotherapy and PharmacologySpringer Journals

Published: Apr 11, 2018

There are no references for this article.